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Abstract
Lacosamide ((R)-N-benzyl 2-acetamido-3-methoxypropionamide, (R)-1) is a low molecular
weight anticonvulsant recently introduced in the United States and Europe for adjuvant treatment
of partial-onset seizures in adults. In this study, we define the structure-activity relationship (SAR)
for the compound's 3-oxy site. Placement of small non-polar, non-bulky substituents at the 3-oxy
site provided compounds with pronounced seizure protection in the maximal electroshock (MES)
seizure test with activities similar to (R)-1. The anticonvulsant activity loss that accompanied
introduction of larger moieties at the 3-oxy site in (R)-1 was offset, in part, by including
unsaturated groups at this position. Our findings were similar to a recently reported SAR study of
the 4′-benzylamide site in (R)-1 (J. Med. Chem.2010, 53, 1288–1305). Together, these results
indicate that both the 3-oxy and 4′-benzylamide positions in (R)-1 can accommodate non-bulky,
hydrophobic groups and still retain pronounced anticonvulsant activities in rodents in the MES
seizure model.
Epilepsy is a common neurological disorder that affects 0.5–1% of the world population.1 It
is a broad term that encompasses many different human seizure types.2,3 The treatment
mainstay for patients with epilepsy has been the long-term and consistent administration of
anticonvulsant drugs, but these agents may be either poorly tolerated or ineffective.4,5
Elucidation of new biological targets for seizure control are expected to provide new
treatment strategies and lead to a better understanding of the pharmacological mechanisms
underlying epileptic disorders.
Lacosamide6 ((R)-1) is a novel antiepileptic drug (AED) that was recently introduced in the
United States and Europe for adjuvant treatment of partial-onset seizures in adults.7 Whole
animal pharmacology studies (e.g., maximal electroshock seizure (MES), chemoconvulsant
seizure tests, Frings mouse model, hippocampal kindled rat test) have revealed a distinctive
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profile for (R)-1 that differentiated it from all other anti-seizure drugs.8 Studies have
appeared concerning the mechanism of action of (R)-1. Radioligand displacement studies
using (R)-1 (10 μM) and more than 100 potential pharmacological targets failed to show
significant binding,9,10 and efforts to detect selective binding in rat brain homogenates with
radiolabeled (R)-1 were unsuccessful.11 These findings suggest that either (R)-1 binds to its
target(s) with modest affinity or its binding partner(s′) levels are too low to be detected or a
combination of both factors. Electrophysiology experiments in neuroblastoma cells
demonstrated that (R)-1 selectively enhanced sodium channel slow inactivation in a time-
and voltage-dependent manner, without affecting fast inactivation.12 Similarly, use of
recombinant human Nav1.3 and NaV1.7 channels and NaV1.8-type tetrodotoxin-resistant
(TTX-R) currents from dorsal root ganglion (DRG) neurons demonstrated that (R)-1
selectively interacted with the slow inactivation state in each of these sodium channel
subtypes.13 Use of (R)-1 analogs designed to irreversibly modify (R)-1 targets preferentially
modified collapsin response mediator protein 2 (CRMP2) in brain lysates.9,14 While
CRMP2 is a signaling protein involved in neuronal differentiation and axonal guidance,15 its
importance in (R)-1 function has not been determined. Thus, the pharmacological actions of
(R)-1 remain elusive.
In 2009, we advanced a strategy to identify molecular drug targets within the proteome
where binding is modest.14 Our approach required attaching an affinity bait (AB) and a
chemical reporter (CR) moiety to the drug framework (Figure 1, 2). The AB group is
designed to irreversibly modify the potential target site(s), and the CR unit permits either the
detection (e.g., by fluorescence) or isolation (e.g., by biotin conjugation) of the covalently
labeled receptor 3 after reaction with a bioorthogonal probe. We outlined the critical
requirements for the AB and CR units.14 Key to the success of this strategy is that the AB
and CR groups in 2 do not impede binding to the cognate receptor(s) of the medicinal agent
that elicit drug function.
We have applied this strategy to search for molecular targets in the rodent brain proteome by
installing AB and CR groups at select sites in (R)-1.14,16 Initial structure-activity
relationship (SAR) studies6 showed that small structural changes at the 3-oxy site in (R)-1
led to modest reductions in anticonvulsant activity indicating that including either an AB or
a CR moiety at this position was possible. Here, we report an in-depth SAR of the 3-oxy site
in (R)-4 and show the importance of size, hydrophobic interactions, and polar modifications
of this site on anticonvulsant activity in the MES seizure test17 in rodents. We include in our
SAR possible AB and CR moieties. We demonstrate that placing non-polar, non-bulky
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substituents at the 3-oxy site provided compounds with pronounced seizure protection in the
MES seizure test. This study complements a recently reported SAR study of the 4′-
benzylamide site in (R)-5.18 Together, these investigations serve as the structural basis for
the design and use of (R)-1 AB&CR agents that can be employed in target-based search
studies. Moreover, they provide important information about the structural elements that can
be incorporated at these (R)-1 sites while still retaining significant protection in animal tests.
Results and Discussion
Choice of compounds
Table 1 lists the (R)-4 3-oxy substituted compounds that constitute the SAR. Our previous
findings show that the anticonvulsant activity for (R)-16 and similar analogs18-21 principally
reside in the D-amino acid derivative, and thus, we synthesized only the (R)-enantiomer for
4. The compounds were evaluated for seizure protection at the Anticonvulsant Screening
Program (ASP) of the National Institute of Neurological Disorders and Stroke (NINDS) at
the National Institutes of Health. We examined several potential interactions that might
affect drug binding. To test for the effect of steric size, we replaced the (R)-1O-methyl unit
with larger alkyl groups ((R)-6–(R)-9). We introduced unsaturated aliphatic and
(hetero)aromatic systems ((R)-10–(R)-16, (R)-18, (R)-19, (R)-26) to look for potential
hydrophobic, π-π, and cationic-π interactions that might facilitate binding.22 Within this set,
we varied the length of the methylene spacer between several of these groups and the 3-oxy
site in (R)-4. Not to limit our study to hydrophobic interactions, we prepared derivatives that
contained a polar side chain ((R)-24, (R)-27, (R)-28). These compounds could accept and/or
donate a hydrogen bond(s) to a suitable amino acid residue within the putative drug binding
pocket(s). Finally, we evaluated (R)-4 oxy-substituted analogs that contained either an AB
((R)-20–(R)-23) or a CR group ((R)-12, (R)-18, (R)-25). In those cases where little or no
anticonvulsant activity was observed for the AB, we prepared the corresponding isostere
(i.e., (R)-16 for (R)-21; (R)-17 for (R)-22; (R)-18 for (R)-23 and (R)-25) to see if either
metabolic factors or structural constraints contributed to the observed activity loss.
Chemistry
We have reported a versatile method for the introduction of 3-oxy substituents within the
(R)-4 framework (Scheme 1).23 The method was adopted from earlier reports showing that
N-substituted aziridines carboxylate esters serve as valuable intermediates in the synthesis of
O-substituted serine amino acid derivatives.24-31,23 To expedite the synthesis of the central
aziridine intermediate (R)-32 from D-serine ((R)-29), we adopted Evans' and coworkers'
cyclodehydration protocol using dialkoxytriphenylphosphoranes (PPh3(OR)2).32-36
Accordingly, serine methyl ester hydrochloride ((R)-30) was sequentially treated with Et3N
and diethoxytriphenylphosphorane (PPh3(OCH2CH3)2, DTPP)37 to give aziridine (R)-31a
and (R)-31b as a mixture of methyl and ethyl esters,23 respectively. The 24-h reaction
provided good yields (50–70%) of (R)-31 after bulb-to-bulb distillation and was used to
prepare multiple grams of (R)-31 in a single experiment. We found that the reaction only
proceeded if (R)-30 was isolated as the free amine.23 Acetylation of (R)-31a and (R)-31b
with acetic anhydride and catalytic amounts of DMAP afforded (R)-32a and (R)-32b.
Treatment of the (R)-32a and (R)-32b mixture with alcohols under Lewis acid-catalyzed
conditions produced the desired 3-oxy substituted serine esters, (R)-33a and (R)-33b, with
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the same C(2) stereochemistry as its precursor.30 The (R)-33a and (R)-33b esters were
hydrolyzed with LiOH to the free acid (R)-34 and then coupled with benzylamine using
either the mixed anhydride coupling method38 or the reagent 4-(4,6-dimethoxy-1,3,5-
triazine-2-yl)-4-methyl-morpholinium chloride (DMTMM).39 Using this protocol, we
prepared (R)-6–(R)-10, (R)-12–(R)-14, (R)-16, (R)-17, (R)-20–(R)-28.
Although DTTP facilitated the production of aziridine esters (R)-31, its preparation was
tedious and required an initial centrifugation step (8000 rpm, 10 min) to remove finely
divided NaBr, and then three or four evaporation/filtration steps to precipitate PPh3(O), a
by-product of the reaction.34 Accordingly, we examined the use of a hexafluoro derivative
of DTPP, PPh3(OCH2CF3)2 (DTPP-F6),40 to generate aziridine (R)-31. DTPP-F6 formation
proceeded faster than DTPP and required only filtration and evaporation to yield the
cyclodehydration reagent.41 Unfortunately, we found that compared with DTPP yields (50–
70%), DTPP-F6 provided lower yields (25–30%) of aziridine (R)-31a after bulb-to-bulb
transfer.
We examined an alternative method to prepare the 3-oxy substituted (R)-4 analogs, wherein
the N-benzyl amide group was installed at an early stage of the synthesis (Scheme 2). (R)-N-
Benzyl 2-amino-3-hydroxypropionamide42 ((R)-36) was obtained by catalytic
hydrogenation of (R)-3542 and then reacted with either DTPP or DTPP-F6 to give (R)-N-
benzyl aziridine-2-carboxamide ((R)-37).14 Following acetylation of (R)-37 to give (R)-38,
the aziridine was ring-opened with 3-butyn-1-ol, and phenethyl alcohol to yield (R)-18, and
(R)-19, respectively. Paralleling the formation of aziridine esters (R)-31a and (R)-31b,
greater yields of (R)-37 were obtained with DTPP (60–70%) over DTPP-F6 (30–35%).
Several factors, however, made this synthetic route (Scheme 2) inconvenient. First, the low
volatility of (R)-37 prevented its bulb-to-bulb distillation, thus requiring silica gel flash
chromatography for purification. Second, we observed in the final step a by-product that was
not readily separated from the desired product by column chromatography. Accordingly, the
pure 3-oxy–substituted (R)-4 derivatives were obtained by recrystallization. We have
tentatively identified the additional product as the acid-catalyzed rearranged31 2-oxazoline
39 on the basis of high resolution mass spectrometry (HRMS) and the characteristic
oxazoline methyl resonance (δ 13.4 ppm) in the 13C NMR spectrum.43 Using this method,
we prepared (R)-18 and (R)-19 on sufficient scale for the pharmacological studies.
Synthesis of the O-benzyl analog (R)-15 was simplified by the commercially availability of
(R)-O-benzylserine ((R)-40). Treatment of (R)-40 with acetic anhydride followed by amide
coupling with benzylamine and DMTMM gave (R)-15 in 93% overall yield (Scheme 3).
For several of the 3-oxy substituted (R)-4 derivatives, the 3-oxy group was modified in the
last step of the synthesis. Aldehyde (R)-21 was prepared from alcohol (R)-41 using Swern
oxidation conditions (Scheme 4).44 Attempts to prepare the corresponding aldehyde AB
derivative containing a single methylene group between the 3-oxy site and the aldehyde
group were unsuccessful. Using the (S)-enantiomer (S)-42, Swern oxidation gave the
cyclized hemiaminal 44 as a ∼9:1 mixture of diastereoisomers with no trace of the desired
product (S)-43 (Scheme 4). We have attributed the difference in Swern oxidation products
44 and (R)-21 to the entropic ease in formation of a six-membered versus the corresponding
seven-membered ring system.45
We used azide (R)-25 to synthesize (R)-24 and (R)-26 (Scheme 5). Catalytic reduction (10%
Pd/C, H2) of (R)-25 gave the terminal amine, which was treated directly with acetic
anhydride and base to give amide (R)-24. When azide (R)-24 was treated with propargyl
methyl ether under Cu(I)-mediated cycloaddition conditions,46 we obtained the triazolyl
derivative (R)-26.14
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The enantiopurity of (R)-6–(R)-10 and (R)-12–(R)-28 were assessed by the detection of a
single acetyl methyl signal in the 1H NMR spectrum for each compound when a saturated
solution of (R)-(-)-mandelic acid was added.47
We report in the Experimental section the details (synthetic procedure, characterization) of
the final step for all new compounds evaluated in the seizure models. In the Supporting
Information section, we provide a synthetic scheme for each new compound tested and the
experimental procedures, physical, and full spectroscopic properties for all new synthetic
compounds prepared in this study.
Pharmacological Activity
Compounds (R)-6–(R)-28 were tested for anticonvulsant activity at the NINDS ASP using
the procedures described by Stables and Kupferberg.48 The pharmacological data from
MES48,49 and 6 Hz50 seizure tests are summarized in Table 1, along with clinical AEDs
phenytoin,51 valproic acid,51 and phenobarbital.51 All compounds were administered
intraperitoneally (ip) to mice and orally (po) to rats, unless otherwise indicated. The table
lists the values determined to be protective in blocking hind limb extension induced in the
MES seizure model from the rodent studies. For compounds that showed significant activity,
we report the 50% effective dose (ED50) obtained in quantitative screening evaluations.
Using the rotorod test52 in mice and the behavioral toxicity effects observed in rats, we
determined the median doses for 50% neurological impairment (TD50). TD50 values were
determined for compounds that exhibited significant activity in the MES seizure test. The
protective index (PI = TD50/ED50) for these analogs are also listed. Select compounds were
evaluated in the psychomotor 6 Hz (32 mA) seizure models (mice, ip).50 When the 3-oxy
(R)-4 derivatives were evaluated in the subcutaneous Metrazol (scMet) seizure model,48
none provided protection at 300 mg/kg doses at the times (0.5 and 4 h) tested (data not
shown), a finding similar to (R)-16 and structurally related compounds.6,14,19-21,53-55
At the beginning of our studies, little was known about the SAR of the 3-oxy site in (R)-4.
Only the anticonvulsant activities of the O-ethyl ((R,S)-6) and the O-allyl (R,S)-11) 4
analogs were reported.6 Both compounds exhibited significant activity but were 2–8-fold
less active then (R,S)-1 in mice (MES ED50 = 8.3 mg/kg).6 Recently, a (R)-4 analog was
prepared wherein the (R)-1 methyl moiety was replaced by the difluoromethyl moiety to
give (R)-45.56 This fluorinated derivative displayed excellent protection and prolonged
duration of action (rat, po) in the MES seizure test (ED50 = 3.0 mg/kg (0.5 h), 4.2 mg/kg (4
h)) when compared with (R)-1 ((ED50 = 1.8 mg/kg (0.5 h), 8.3 mg/kg (4 h)) under the same
test conditions.56 Our development of a general, versatile method to prepare
enantiomerically pure 3-oxy–substituted (R)-4 derivatives through N-acetyl aziridine
(R)-3223 permitted us to explore the SAR of the 3-oxy position.
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In total, 23 O-substituted (R)-4 analogs were prepared and evaluated for anticonvulsant
activity at the NINDS ASP (Table 1). We observed a steady increase in activity in mice (ip)
as the steric size of the (R)-4 R substituent decreased from cyclohexyl ((R)-9, ED50 = 100–
300 mg/kg) and tert-butyl ((R)-8, ED50 = 30–100 mg/kg) to isopropyl ((R)-7, ED50 = 23 mg/
kg), to ethyl ((R)-6, ED50 = 7.9 mg/kg), and to methyl ((R)-1, ED50 = 4.5 mg/kg), indicating
that non-bulky 3-oxy substituted groups in (R)-4 analogs provided the highest anticonvulsant
activity.23 Interestingly, we observed a similar increase in activity as the size of the 3-oxy
substituent decreased when the compounds were administered orally to rats, but the range of
activities was narrower. For example, the O-cyclohexyl derivative (R)-9 exhibited an ED50
of ∼30 mg/kg while O-isopropyl (R)-7 (ED50 = 5.6 mg/kg), O-ethyl (R)-6 (ED50 = 5.2 mg/
kg), and O-methyl (R)-1 (ED50 = 3.9 mg/kg) all displayed excellent seizure protection. (R)-6
and (R)-7 showed no behavioral neurotoxicity in the rat at the highest dose (500 mg/kg)
tested, leading to high PI values for both compounds ((R)-6: PI >89; (R)-7: PI >58). We
concluded that including bulky alkyl substituents at the 3-oxy site in (R)-4 adversely
affected seizure protection in the MES seizure test.
Inserting one methylene (CH2) group between the oxygen and the cyclohexyl ring in (R)-9
(ED50 = 100-300 mg/kg) to give (R)-14 (ED50 = 100–300 mg/kg) did not improve activity in
mice (ip). However, we observed a pronounced increase in potency in mice (ip) going from
O-phenyl (R)-10 (ED50 = 100–300 mg/kg)23 to O-benzyl (R)-15 (ED50 = 64 mg/kg).
We also found notable anticonvulsant activity for other derivatives that contained an
unsaturated substituent one methylene group separated from the 3-oxy site in (R)-4. The O-
allyl6 ((R,S)-11, ED50 = 30–100 mg/kg), O-propargyl ((R)-12, ED50 = 16 mg/kg),14 and O-
but-2-ynyl ((R)-13, ED50 = 30–100 mg/kg) (R)-1 analogs all provided pronounced seizure
protection in mice (ip). When the O-propargyl ((R)-12, ED50 = 7.9 mg/kg) and the O-but-2-
ynyl ((R)-13, ED50 = 6.4 mg/kg) (R)-4 derivatives were tested in the rat (po) we observed
excellent seizure protection, which was comparable with phenytoin (ED50 = 30 mg/kg)51
and phenobarbital (ED50 = 9.1 mg/kg),51 and no behavioral neurological toxicity at 500 mg/
kg. Significantly, the propargyl unit was shown to be a superior CR unit in bioorthogonal
Cu(I)-mediated cycloaddition reactions.14,57 Our finding that (R)-12 and (R)-13 exhibited
excellent activity in the MES seizure model indicated that this CR unit in (R)-1 AB&CR
agents would not likely impact the unit's binding to its cognate receptor(s).
We next explored the effect of adding a second methylene unit between the unsaturated unit
and the (R)-4 3-oxy site to determine if the location of the unsaturated site affected
anticonvulsant activity. When we added the second methylene group to O-propargyl (R)-12
(ED50 = 16 mg/kg) and O-benzyl (R)-15 (ED50 = 64 mg/kg) to give O-3-butynyl (R)-18
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(ED50 = 30–100 mg/kg) and O-2-phenylethyl (R)-19 (ED50 = 100–300 mg/kg) (R)-4
derivatives, we saw a decrease in anticonvulsant activity in mice (ip). Like the O-
phenylethyl derivative (R)-19 (ED50 = 100-300 mg/kg), the O-triazolylethyl (R)-26
compound (ED50 = >300 mg/kg) did not display activity in mice (ip) at the doses tested.
Nonetheless, when tested orally in rats, the O-3-butynyl (R)-18 (ED50 = 11 mg/kg) provided
excellent seizure protection. These results indicated that the site of unsaturation at the 3-oxy
site in (R)-4 may be important for anticonvulsant activity. We observed one exception to this
pattern, the O-allyl ((R,S)-11, ED50 = 30–100 mg/kg) and the O-3-butenyl ((R)-16, ED50 =
30–100 mg/kg) (R)-4 derivatives showed similar anticonvulsant activity in mice (ip). Like
O-3-butynyl (R)-18, the activity of the O-3-butenyl (R)-16 derivative improved from mice
(ip) (ED50 = 30–100 mg/kg) to rat (po) (ED50 = 17 mg/kg). Collectively, these findings
suggested that a favorable interaction with the 3-oxy π system in (R)-4 at the target site(s)
may foster binding, provided the group was not large and the unsaturated system was
correctly positioned at the 3-oxy site.
The effect of polar substituents at the C(2) site in (R)-4 was assessed by incorporating either
an ethylenoxy or an acetamidoethoxy unit two methylene units removed from the 3-oxy site.
When we attached one ethylenoxy group to give methyl ether (R)-27, we observed
noticeable seizure protection (ED50 = 30–100 mg/kg) in mice (ip). Adding a second
ethylenoxy spacer to (R)-27 to give (R)-28 produced no detectable activity under
comparable test conditions (ED50 = >300 mg/kg). Similarly, the acetamidoethyl analog
(R)-24 (ED50 = >300 mg/kg) was inactive at the doses tested. The limited data do not allow
us to speculate on the factors (e.g., (R)-4 biodistribution in the brain, metabolism, drug
binding) responsible for the loss of anticonvulsant activity of (R)-24 and (R)-28.
Nonetheless, our findings indicated that introducing polar substituents at the 3-oxy site in
(R)-4 did not improve seizure protection, and provided valuable information for the
installation of both AB and CR units in the (R)-1 framework and for future drug design
efforts.
We tested (R)-4 derivatives, (R)-21–(R)-23, that contained AB groups at their 3-oxy sites.
The electrophilic groups aldehyde (R)-21 (ED50 = >300 mg/kg) and epoxide (R)-22 (ED50 =
>300 mg/kg) exhibited no anticonvulsant activity and no neurological toxicity at the doses
tested in mice (ip). The lack of neurotoxicity may suggest that the compounds did not cross
the blood brain barrier. The aliphatic isothiocyanate (R)-23 was inactive in mice (ED50 =
>300 mg/kg), active in rats (ED50 = <30 mg/kg), but neurologically toxic (TD50 = 30–100
mg/kg, mice (ip); TD50 = >30 mg/kg, rat (po)). We suspect that several of these AB groups
may have undergone change or been metabolized under the test conditions. Indeed,
aldehydes and epoxides are known substrates for a variety of enzymes (e.g., aldehyde
reductases, epoxide hydrolases).58-63 Since we planned to use these AB groups for in vitro
experiments where metabolism would less likely be an issue, we evaluated, where possible,
the corresponding AB isostere to determine if the steric size of the AB group precluded their
use. We were gratified to find that the O-but-3-enyl isostere (R)-16 (ED50 = 30–100 mg/kg,
mice (ip); ED50 = 17 mg/kg, rat (po)) for aldehyde (R)-21 and the O-cyclopropyl isostere
(R)-17 (ED50 = 46 mg/kg. mice (ip)) for epoxide (R)-22 displayed pronounced-to-excellent
anticonvulsant activity. Thus, we have not attributed the absence of activity for aldehyde
(R)-21 and epoxide (R)-22 to steric factors. Similar to the O-cyclopropyl (R)-17, the
photolabile methyldiazirine AB derivative (R)-20 exhibited pronounced animal protection in
the MES seizure test (ED50 = 30–100 mg/kg, mice (ip); ED50 = 44 mg/kg, rat (po)).
Several (R)-4 compounds were prepared that contained a CR unit at the 3-oxy site ((R)-12,
(R)-18, (R)-25). The alkyne (R)-12 and azide (R)-25 CR compounds displayed excellent
anticonvulsant activity (ED50 = <10 mg/kg) in the rat upon po and ip administration,
respectively. These findings supported the use of these CR units in (R)-1 proteomic target
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searches. Of all the (R)-4 3-oxy substituted analogs prepared, the whole animal
pharmacology of O-azidoethyl analog (R)-25 was the most intriguing. (R)-25 anticonvulsant
activity was dependent on the animal, the seizure test, and the route of administration. While
(R)-25 displayed poor MES seizure protection in mice (ip) (ED50 = 100–300 mg/kg), it
proved potent in the 6 Hz (32 mA) test50 when also administered ip to mice (ED50 = 44 mg/
kg). Furthermore, we observed that (R)-25 exhibited exceptional activity in the MES seizure
test in the rat when administered ip (ED50 = 5.7 mg/kg) but that activity dropped with po
administration (MES ED50 = >40 mg/kg). When administered ip to the rat, the TD50 for
(R)-25 was 78 mg/kg, providing a PI greater than 13.
Finally, we asked whether that a methyl-d3 analog of (R)-1, (R)-1-d3, would display
enhanced anticonvulsant activity over (R)-1. Recently, pharmaceutical companies have
prepared deuterated versions (“heavy drugs”) of marketed medicinal agents.64 The greater
strength of C–D bonds compared with C–H bonds is predicted to confer increased metabolic
stability for the deuterated version of the drug.64 Significantly, the major metabolite for
(R)-1 in humans is the desmethyl analog (R)-46.8 The metabolic conversion of (R)-1 to
(R)-46 has not been attributed to a specific metabolic enzyme.65 Nonetheless, (R)-46
accounts for ∼30% of the (R)-1 excreted in human urine,66 and it exhibits little
anticonvulsant activity (ED50 = 100–300 mg/kg).6 Accordingly, we reasoned that replacing
the 3-oxy methyl group in (R)-1 with the perdeuterated methyl unit to give (R)-1-d3 might
reduce metabolic processes and thus lead to increased bioavailability of the AED. We
prepared (R)-1-d3 using a method we reported for (R)-142 and substituting CD3I for CH3I.
The deuterated derivative (R)-1-d3 (ED50 = 5.2 mg/kg) showed an anticonvulsant activity in
the rat (po) comparable with (R)-1 (ED50 = 3.9 mg/kg), without exceeding it, and exhibited
greater neurological toxicity ((R)-1-d3, TD50 = ∼200 mg/kg; (R)-1, TD50 = >500 mg/kg).
Conclusions
This SAR study demonstrated that replacing the 3-oxy methyl group in (R)-1 with small,
non-bulky, hydrophobic groups provided derivatives with pronounced anticonvulsant
activity in the MES seizure model. We showed that substituting the 3-oxy methyl group in
(R)-1 with larger alkyl groups diminished activity, but the loss could be offset, in part, by the
incorporating hydrophobic, unsaturated moieties. Our SAR findings for the 3-oxy site in
(R)-4 were similar to that observed for the 4′-benzylamide position in (R)-5, where non-
bulky, hydrophobic groups provided derivatives with excellent anticonvulsant activities18
(Figure 2). Most important, these findings support our use of (R)-1 AB&CR agents in
proteomic searches wherein either the AB or the CR unit is installed at the 3-oxy site.
Experimental Section
General Methods
The general methods used in this study were identical to those previously reported14 and are
summarized in the Supporting Information Section. All compounds were checked by
TLC, 1H and 13C NMR, MS, and elemental analyses. The analytical results are within
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+0.40% of the theoretical value. The TLC, NMR and the analytical data confirmed the
purity of the products was ≥95%.
General Procedure for the Pd-catalyzed Hydrogenation Reaction. Method A
A MeOH suspension of the starting material ([C] ∼0.01–0.2 M) and 10% Pd/C (10% w/w)
was vigorously stirred under an atmosphere of H2 (balloon) at room temperature (16 h). The
mixture was filtered through a bed of Celite®. The bed was washed with MeOH and
CH2Cl2, the washings were collected and evaporated in vacuo. The amine was used without
further purification.
General Procedure for the Ester Hydrolysis of (R)-33 with LiOH. Method B
To a THF solution of ester (R)-33 (2 volumes, [C] ∼0.1 M) was added an aqueous solution
(1 volume) of LiOH (1 equiv). The homogeneous solution was stirred at room temperature
(60 min), after which time Et2O (2 volumes) was added. The aqueous layer was recovered,
and washed with Et2O. The remaining aqueous layer was acidified (pH ∼1) by the dropwise
addition of aqueous concentrated HCl, saturated with NaCl, and extracted with EtOAc until
no further product was detected (TLC analysis). The combined organic layers were
combined, dried (Na2SO4), and evaporated to an oily residue that was used directly for the
next step or recrystallized from EtOAc and hexanes to provide an analytical sample.
General Procedure for the DMTMM Amide Coupling Reaction.39 Method C
To a THF solution of acid (R)-34 ([C] ∼0.1 M) at room temperature was added the desired
benzylamine (1.2 equiv). The solution was stirred (5–10 min) until the benzylammonium
carboxylate precipitated. With stirring, DMTMM (1.2 equiv) was added all at once, and the
resulting suspension was stirred at room temperature (3–12 h). In those cases where a salt
did not precipitate, DMTMM was added after 15 min to the solution. The salts were
removed by filtration and washed with THF, and the solvent was removed in vacuo. The
residue obtained was purified by flash column chromatography to afford the benzylamide,
and then recrystallized from EtOAc and hexanes.
General Procedure for the Aziridine Ring-Opening of (R)-32 and (R)-38 with Alcohols.
Method D
To a cooled CH2Cl2 solution (ice bath) of either (R)-32 or (R)-38 ([C] ∼0.5–1 M) and the
appropriate alcohol (1-5 equiv) was added BF3•Et2O (1 equiv) dropwise while stirring. After
addition, the mixture was warmed to room temperature and stirred (30 min), and then an
equal volume of saturated aqueous NaHCO3 was added. The reaction was vigorously stirred
(15 min) and the organic layer separated. The aqueous layer was extracted with CH2Cl2
until no additional product could be detected (TLC analysis). All the organic layers were
then combined, dried (Na2SO4), and concentrated in vacuo to yield a residue that was either
purified by flash column chromatography, used directly for the next step or recrystallized
from EtOAc and hexanes.
(R)-N-Benzyl 2-Acetamido-3-(methoxy-d3)propionamide ((R)-1-d3)—Using
Method A, (R)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-(methoxy-d3)propionamide (1.5
g, 4.25 mmol) and 10% Pd/C (200 mg) in MeOH (50 mL) gave after evaporation an oily
residue that was directly dissolved in CH2Cl2 (50 mL). While stirring Et3N (590 μL, 4.25
mmol), DMAP (25 mg, 212 μmol) and Ac2O (400 μL, 4.25 mmol) were successively added
and the reaction was stirred at room temperature (1 h). The organic layer was washed with
aqueous 0.1 M H2SO4 (20 mL). The aqueous layer was extracted with CH2Cl2 (4 × 20 mL).
The organic layers were combined, washed with brine (50 mL), dried (Na2SO4), and the
solvents were removed under vacuum. The obtained solid was recrystallized from EtOAc
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and hexanes to give (R)-1-d3 as a white solid (888 mg, 82% over 2 steps): mp 142–143 °C;
[α]25D +16.0° (c 0.7, MeOH); Rf = 0.31 (5/95 MeOH/CH2Cl2); 1H NMR (CDCl3) δ 1.97 (s,
3H), 3.47 (dd, J = 6.6, 9.0 Hz, 1H), 3.84 (dd, J = 4.0, 9.0 Hz, 1H), 4.34–4.52 (m, 2H), 4.55–
4.69 (m, 1H), 6.72 (d, J = 7.0 Hz, 1H), 7.05–7.16 (m, 1H), 7.20–7.38 (m, 5H); Mr (+ESI)
276.1 [M+Na]+ (calcd for C13H15D3N2O3Na+ 276.1). Anal. (C13H15D3N2O3): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(2-cyclohexyloxy)propionamide ((R)-9)—Using
Method B, a ∼1:1 mixture of (R)-methyl 2-acetamido-3-(cyclohexyloxy)propionate and (R)-
ethyl 2-acetamido-3-(cyclohexyloxy)propionate (2.10 g, 8.4 mmol) in THF (80 mL) and
LiOH (202 mg, 8.4 mmol) in H2O (40 mL) gave upon work-up the corresponding acid (1.62
g, 7.1 mmol, 84%) as a yellow viscous oil (Mr (+ESI) 252.1212 [M+Na]+ (calcd for
C11H19NO4Na+ 252.1204)) that was directly dissolved in THF (70 mL). Using Method C,
addition of benzylamine (930 μL, 8.5 mmol) and DMTMM (2.4 g, 8.5 mmol) gave (R)-9 as
a white solid (1.17 g, 65%) after purification by flash chromatography (1:2 hexanes/EtOAc
to 1/9 MeOH/CH2Cl2) followed by recrystallization from EtOAc and hexanes: mp 134–135
°C; [α]25D -33.5° (c 1.2; CHCl3); Rf = 0.52 (EtOAc); 1H NMR (CDCl3) δ 1.10–1.34, 1.42–
1.88 (m, 10H), 2.03 (s, 3H), 3.24–3.36 (m, 1H), 3.43 (app. t, J = 9.0 Hz, 1H), 3.86 (dd, J =
3.6, 9.0 Hz, 1H), 4.38–4.56 (m, 3H), 6.48–6.58 (br d, 1H), 6.92–7.02 (br t, 1H), 7.22–7.38
(m, 5H); Mr (+ESI) 341.3 [M+Na]+ (calcd for C18H26N2O3Na+ 341.3). Anal.
(C18H26N2O3): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(but-2-yn-1-yloxy)propionamide ((R)-13)—To a
cooled (-78 °C) solution of (R)-2-acetamido-3-(but-2-ynyloxy)propionic acid (1.15 g, 5.78
mmol) in THF (50 mL), were successively added N-methylmorpholine (NMM) (0.95 mL,
8.67 mmol), stirred (2 min), isobutylchloroformate (IBCF) (0.95 mL, 7.28 mmol), stirred
(15 min), and benzylamine (0.75 mL, 6.94 mmol).38 The reaction was allowed to warm to
room temperature and further stirred (2 h), filtered, and concentrated in vacuo. Purification
by flash chromatography (1/9 MeOH/CHCl3) gave 1.53 g (92%) of (R)-13 as a white solid:
mp 149–151 °C; [α]25D -34.2° (c 0.5, CHCl3); Rf = 0.45 (1/9 MeOH/CHCl3); 1H NMR
(CDCl3) δ 1.83 (t, J = 2.4 Hz, 3H), 2.03 (s, 3H), 3.61 (dd, J = 7.2, 9.3 Hz, 1H), 3.90 (dd, J =
4.2, 9.3 Hz, 1H), 4.08–4.21 (m, 2H), 4.41–4.54 (m, 2H), 4.57–4.63 (m, 1H), 6.48–6.51 (br d,
J = 6.6 Hz, 1H), 6.77–6.84 (br m, 1H), 7.25–7.37 (m, 5H); Mr (+ESI) 288.1 [M+H]+ (calcd
for C16H20N2O3H+ 288.1). Anal. (C16H20N2O3) C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(2-cyclohexylmethoxy)propionamide ((R)-14)—
Using Method B, a ∼1:4 mixture of (R)-methyl 2-acetamido-3-
(cyclohexylmethoxy)propionate and (R)-ethyl 2-acetamido-3-
(cyclohexylmethoxy)propionate (2.32 g, 8.6 mmol) in THF (85 mL) and LiOH (207 mg, 8.6
mmol) in H2O (40 mL) gave upon work-up the corresponding acid (1.88 g, 7.7 mmol, 90%)
as a yellow viscous oil that was directly dissolved in THF (75 mL). Using Method C,
addition of benzylamine (1.0 mL, 9.2 mmol) and DMTMM (2.54 g, 9.2 mmol) gave (R)-14
as a white solid (1.50 g, 59%) after purification by flash chromatography (1:2 hexanes/
EtOAc to 1/9 MeOH/CH2Cl2) followed by recrystallization from EtOAc and hexanes: mp
143–144 °C; [α]25D +6.7° (c 1.6; MeOH); Rf = 0.39 (5/95 MeOH/CH2Cl2); 1H NMR
(CDCl3) δ 0.74–0.90, 1.00–1.26, 1.40–1.72 (m, 11H), 2.02 (s, 3H), 3.16–3.32 (m, 2H), 3.42
(app. t, J = 9.0 Hz, 1H), 3.79 (dd, J = 3.6, 9.0 Hz, 1H), 4.38–4.50 (m, 2H), 4.51–4.60 (m,
1H), 6.53 (d, J = 6.3 Hz, 1H), 6.88–7.00 (br t, 1H), 7.22–7.38 (m, 5H); Mr (+ESI) 355.1998
[M+Na]+ (calcd for C19H28N2O3Na+ 355.1997). Anal. (C19H28N2O3): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(benzyloxy)propionamide ((R)-15)—To a stirred
suspension of O-benzyl-D-serine (Astatech Inc.) (1.00 g, 5.13 mmol) in a 9:1 THF:H2O
mixture (50 mL) was added Ac2O (1.45 mL, 15.3 mmol) at room temperature and the
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reaction was stirred at room temperature (3 h). The solvents were removed in vacuo to yield
a viscous clear residue (1.22 g, 5.13 mmol, quant.) that was directly dissolved in THF (60
mL). Using Method C, benzylamine (670 μL, 6.2 mmol) and DMTMM (1.71 g, 6.2 mmol)
gave (R)-15 as a white solid (1.55 g, 93% for 2 steps) upon purification by flash
chromatography (EtOAc to 1/9 MeOH/CH2Cl2): mp 145–146 °C; [α]25D -28.7° (c 0.7;
CHCl3); Rf = 0.49 (EtOAc); 1H NMR (CDCl3) δ 2.01 (s, 3H), 3.51 (dd, J = 7.8, 9.0 Hz, 1H),
3.90 (dd, J = 4.2, 9.0 Hz, 1H), 4.38–4.64 (m, 5H), 6.40–6.52 (br d, 1H), 6.72–6.84 (br t, 1H),
7.18–7.38 (m, 10H); Mr (+ESI) 349.2 [M+Na]+ (calcd for C19H22N2O3Na+ 349.2). Anal.
(C19H22N2O3): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(but-3-enyloxy)propionamide ((R)-16)—Using
Method C, (R)-2-acetamido-3-(but-3-en-1-yloxy)propionic acid (1.32 g, 6.57 mmol),
benzylamine (860 μL, 7.88 mmol), and DMTMM (2.18 g, 7.88 mmol) gave (R)-16 (1.30 g,
67%) as a white solid after purification by flash chromatography (EtOAc) and further
recrystallization from EtOAc and hexanes: mp 103–104 °C; [α]25D +51.3° (c 0.6; MeOH);
Rf = 0.37 (5/95 MeOH/CH2Cl2); 1H NMR (CDCl3) δ 2.03 (s, 3H), 2.22–2.36 (m, 2H), 3.40–
3.62 (m, 3H), 3.85 (dd, J = 4.2, 9.0 Hz, 1H), 4.45 (d, J = 7.2 Hz, 2H), 4.48–4.57 (m, 1H),
4.92–5.06 (m, 2H), 5.62–5.74 (m, 1H), 6.42–6.56 (m, 1H), 6.84–6.96 (br t, 1H), 7.20–7.36
(m, 5H); Mr (+ESI) 313.1528 [M+Na]+ (calcd for C16H22N2O3Na+ 313.1528). Anal.
(C16H22N2O3): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(2-cyclopropylethoxy)propionamide ((R)-17)—
Using Method B, a ∼1:1 mixture of (R)-methyl 2-acetamido-3-(2-
cyclopropylethoxy)propionate and (R)-ethyl 2-acetamido-3-(2-
cyclopropylethoxy)propionate (1.60 g, 6.6 mmol) in THF (60 mL) and LiOH (158 mg, 6.6
mmol) in H2O (30 mL) gave upon work-up the corresponding acid (1.27 g, 5.9 mmol, 90%)
as a yellow oil (Mr (+ESI) 238.1056 [M+Na]+ (calcd for C10H17NO4Na+ 238.1054)) that
was directly dissolved in THF (60 mL). Using Method C, addition of benzylamine (740 μL,
7.13 mmol) and DMTMM (2.0 g, 7.13 mmol) gave (R)-17 as a white solid (1.17 g, 65%)
after purification by flash chromatography (1:2 hexanes/EtOAc to 1/9 MeOH/CH2Cl2)
followed by recrystallization from EtOAc and hexanes: mp 97–99 °C; [α]25D -32.1° (c 1.5;
MeOH); Rf = 0.52 (EtOAc); 1H NMR (CDCl3) δ-0.08–0.01 (m, 2H), 0.30–0.38 (m, 2H),
0.50–0.64 (m, 1H), 1.32–1.48 (m, 2H), 2.02 (s, 3H), 3.40–3.62 (m, 3H), 3.84 (dd, J = 3.9,
9.0 Hz, 1H), 4.38–4.58 (m, 3H), 6.48–6.58 (br d, 1H), 6.90–7.00 (br t, 1H), 7.20–7.36 (m,
5H); Mr (+ESI) 327.2 [M+Na]+ (calcd for C17H24N2O3Na+ 327.2). Anal. (C17H24N2O3): C,
H, N.
(R)-N-Benzyl 2-Acetamido-3-(but-3-ynyloxy)propionamide ((R)-18)—Using
Method D, compound (R)-38 (1.14 g, 5.22 mmol), homopropargyl alcohol (2.0 mL, 26.1
mmol), and BF3•Et2O (500 μL, 3.97 mmol) in CH2Cl2 (30 mL) gave (R)-18 as a white solid
(450 mg, 30%) upon work-up, purification by flash chromatography (2/1 EtOAc/CH2Cl2),
and subsequent recrystallization from EtOAc and hexanes: mp 120–122 °C; [α]25D -49.1° (c
0.8, CHCl3); Rf = 0.38 (2/1 EtOAc/CH2Cl2); 1H NMR (CDCl3) δ 1.80 (t, J = 2.7 Hz, 1H),
2.04 (s, 3H), 2.38– 2.46 (m, 2H), 3.46–3.74 (m, 3H), 3.90 (dd, J = 3.9, 9.0 Hz, 1H), 4.38–
4.58 (m, 3H), 6.48–6.56 (m, 1H), 6.92–7.06 (m, 1H), 7.20–7.38 (m, 5H); Mr (+ESI) 421.1
[M+Cs]+ (calcd for C16H20N2O3Cs+ 421.1). Anal. (C16H20N2O3): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-phenethoxypropionamide ((R)-19)—Using Method
D, compound (R)-38 (2.00 g, 9.2 mmol), phenethyl alcohol (6.0 mL, 49.2 mmol), and
BF3•Et2O (1.0 mL, 8.0 mmol) in CH2Cl2 (30 mL) gave (R)-19 as a white solid (392 mg,
10%) upon work-up and purification by flash chromatography (2/1 EtOAc/CH2Cl2) and
recrystallization from EtOAc and hexanes: mp 90–92 °C; [α]25D -29.2° (c 0.5, CHCl3); Rf =
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0.44 (3/1 EtOAc/CH2Cl2); 1H NMR (CDCl3) δ 1.97 (s, 3H), 2.84 (d, J = 6.3 Hz, 2H), 3.40
(app d, J = 8.1 Hz, 1H), 3.62–3.92 (m, 3H), 4.20–4.38 (m, 2H), 4.40–4.50 (m, 1H), 6.32–
6.40 (m, 1H), 6.50–6.62 (m, 1H), 7.12–7.38 (m, 10H); Mr (+ESI) 363.2 [M+Na]+ (calcd for
C20H24N2O3Na+ 363.2). Anal. (C20H24N2O3): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)propionamide
((R)-20)—Using Method C, (R)-2-acetamido-3-(2-(3-methyl-3H-diazirin-3-
yl)ethoxy)propionic acid (500 mg, 2.2 mmol), benzylamine (285 μL, 2.6 mmol) and
DMTMM (723 mg, 2.6 mmol) in THF (22 mL) gave (R)-20 as a white solid (565 mg, 81%)
after purification by flash chromatography (3/2 hexanes/EtOAc to EtOAc to 3/2 EtOAc/
acetone): Rf = 0.43 (EtOAc); mp 120–121 °C; [α]24.1D -33.4° (c 0.5, CHCl3); 1H NMR
(CDCl3) δ 0.98 (s, 3H), 1.65 (t, J = 6.0 Hz, 2H), 2.07 (s, 3H), 3.14–3.22 (m, 1H), 3.33–3.44
(m, 2H), 3.84 (dd, J = 3.6, 9.0 Hz, 1H), 4.44–4.58 (m, 3H), 6.63 (d, J = 6.3 Hz, 1H), 6.97–
7.05 (br t, 1H), 7.24–7.37 (m, 5H); Mr (+ESI) 319.1769 [M+H]+ (calcd C16H22N4O3H+
319.1770). Anal. (C16H22N4O3): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(3-oxopropoxy)propionamide ((R)-21)—To a cooled
solution (dry ice/acetone bath) of oxalyl chloride (432 μL, 4.92 mmol) in CH2Cl2 (12 mL)
was added dropwise a solution of DMSO (720 μL, 9.84 mmol) in CH2Cl2 (24 mL). After
stirring at -78 °C (15 min) a solution of (R)-N-benzyl 2-acetamido-3-(3-
hydroxypropoxy)propionamide (1.20 g, 4.08 mmol) in CH2Cl2 (12 mL) was added dropwise
at -78 °C and the reaction was stirred at -78 °C (1 h). DIEA (3.55 mL, 14.4 mmol) was then
added dropwise, stirred (20 min), warmed to room temperature and then stirred (30 min).
Aqueous 10% citric acid (50 mL) was added to the solution and the CH2Cl2 layer was
separated. The aqueous layer was extracted with CH2Cl2 (6 × 50 mL), the combined organic
layers were washed with brine (50 mL), dried (Na2SO4), and evaporated to give an oily
residue that was recrystallized from EtOAc and hexanes to afford (R)-21 as white needles:
mp 120–121 °C; [α]25D -22.1° (c 0.9, CHCl3); Rf = 0.34 (5/95 MeOH/CHCl3); 1H NMR
(CDCl3) δ 2.04 (s, 3H), 2.60–2.80 (m, 2H), 3.48 (dd, J = 7.5, 9.3 Hz, 1H), 3.70–3.78 (m,
1H), 3.80–3.87 (m, 1H), 3.90 (dd, J = 3.6, 9.3 Hz, 1H), 4.46 (d, J = 6.0 Hz, 2H), 4.51–4.58
(m, 1H), 6.61 (d, J = 6.3 Hz, 1H), 6.85–7.04 (br t, 1H), 7.22–7.38 (m, 5H), 9.71 (t, J = 1.4
Hz, 1H); Mr (+ESI) 315.1323 [M+Na]+ (calcd for C15H20N2O4Na+ 315.1321). Anal.
(C15H20N2O4): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(2-(oxiran-2-yl)ethoxy)propionamide ((R)-22)
(mixture of diastereomers)—A solution of mCPBA (77% wt, 420 mg, 1.88 mmol) in
CH2Cl2 (3 mL) was stirred in the presence of Na2SO4 (∼50 mg, 5 min) and (R)-16 (320 mg,
1.10 mmol) was added at once. The suspension was stirred at room temperature (15 h),
filtered, concentrated under vacuum to give (R)-22 (265 mg, 72%) as a ∼1:1 mixture of
diastereoisomers after purification by flash chromatography (15/85 acetone/EtOAc): mp
104–110 °C; [α]25D -29.6° (c 0.3; CHCl3); Rf = 0.31 (15/85 acetone/EtOAc); 1H NMR
(CDCl3) δ 1.52–1.64 (m, 1H), 1.86–2.00 (m, 1H), 2.03, 2.04 (s, 3H), 2.41–2.46 (m, 1H),
2.66–2.71 (m, 1H), 2.82–2.96 (m, 1H), 3.44–3.52 (m, 1H), 3.54–3.76 (m, 2H), 3.84–3.93
(m, 1H), 4.39–4.52 (m, 2H), 4.50–4.58 (m, 1H), 6.56–6.68 (m, 1H), 6.88–6.98, 6.99–7.08
(m, 1H), 7.22–7.36 (m, 5H); Mr (+ESI) 329.1478 [M+Na]+ (calcd for C16H22N2O4Na+
329.1477). Anal. (C16H22N2O4): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(2-acetamidoethoxy)propionamide ((R)-24)—Using
Method A, (R)-25 (1.14 g, 3.7 mmol) and 10% Pd/C (100 mg) in MeOH (25 mL) gave upon
filtration and evaporation a residue that was dissolved in CH2Cl2 (50 mL). Et3N (570 μL,
4.1 mmol), DMAP (1 mg, catalytic), and Ac2O (390 μL, 4.1 mmol) were then successively
added and the reaction was stirred at room temperature (30 min), filtered, and the solvents
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were removed under vacuum. The crude residue was purified by flash chromatography (1/9
MeOH/CH2Cl2) to give an oily residue that was dissolved in warm THF (25 mL). The white
solid that precipitated upon cooling was filtered to give (R)-24 (490 mg, 40% overall yield
for two steps): mp 166–168 °C; [α]25D +11.7° (c 0.6, MeOH); Rf = 0.30 (5/95 MeOH/
CH2Cl2); 1H NMR (DMSO-d6) δ 1.79, 1.88 (s, 6H), 3.10–3.24 (m, 2H), 3.36–3.46 (m, 2H),
3.52–3.64 (m, 2H), 4.29 (d, J = 7.0 Hz, 2H), 4.42–4.52 (m, 1H), 7.20–7.36 (m, 5H), 7.80–
7.88 (m, 1H), 8.07 (d, J = 7.0 Hz, 1H), 8.50 (t, J = 6.0 Hz, 1H); Mr (+ESI) 344.2 [M+Na]+
(calcd for C16H23N3O4Na+ 344.2). Anal. (C16H23N3O4): C, H, N.
(R)-N-Benzyl 2-Acetamido-3-(2-methoxyethoxy)propionamide ((R)-27)—Using
Method B, a ∼5:95 mixture of (R)-methyl 2-acetamido-3-(2-methoxyethoxy)propionate and
(R)-ethyl 2-acetamido-3-(2-methoxyethoxy)propionate (4.00 g, 17.4 mmol) in THF (170
mL) and LiOH (415 mg, 17.3 mmol) in H2O (80 mL) gave 1.10 g (31%, 5.36 mmol) of a
crude viscous yellow oil upon work-up (Mr (+ESI) 228.0848 [M+Na]+ (calcd for
C8H15NO5Na+ 228.0848)). Using Method C, the oil was directly dissolved in THF (60 mL)
and then benzylamine (732 μL, 6.7 mmol) followed by DMTMM (1.90 g, 6.7 mmol) were
added. Purification by flash chromatography (1/9 hexanes/EtOAc to 1/9 MeOH/CH2Cl2)
followed by recrystallization from EtOAc and hexanes afforded (R)-27 (750 mg, 45%) as a
white solid: mp 109–110 °C; [α]25D +10.3° (c 0.5; MeOH); Rf = 0.43 (1/9 MeOH/
CH2Cl2); 1H NMR (CDCl3) δ 2.02 (s, 3H), 3.18 (s, 3H), 3.43–3.53 (m, 3H), 3.62–3.78 (m,
2H), 3.85 (dd, J = 4.2, 9.6 Hz, 2H), 4.37–4.51 (m, 2H), 4.52–4.58 (m, 1H), 6.65 (d, J = 6.6
Hz, 1H), 7.21–7.38 (m, 6H); Mr (+ESI) 317.1478 [M+Na]+ (calcd for C15H22N2O4Na+
317.1477). Anal. (C15H22N2O4): C, H, N.
Pharmacology—Compounds were screened under the auspices of the National Institutes
of Health's Anticonvulsant Screening Program. Experiments were performed in male rodents
[albino Carworth Farms No. 1 mice (intraperitoneal route, ip), albino Spague-Dawley rats
(oral route, po)]. Housing, handling, and feeding were in accordance with recommendations
contained in the ‘Guide for the Care and Use of Laboratory Animals’. Anticonvulsant
activity was established using the MES test,53,54 6 Hz,55 and the scPTZ test,53 according to
previously reported methods.6
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Use of the AB&CR Strategy to Identify Potential Drug Receptors.
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Structural sites in (R)-1 where incorporation of non-polar groups substituents lead to
pronounced anticonvulsant activity in the MES seizure model.
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Synthetic pathway to enantiopure (R)-4 derivatives using N-acetyl aziridine ester (R)-32
ring-opening.
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Alternative synthetic pathway to O-substituted derivatives (R)-4.
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Synthesis of (R)-1 Derivative (R)-15.
Morieux et al. Page 22














Synthesis of (R)-21 and 44.
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Synthesis of (R)-24 and (R)-26.
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